Alcea is a Russian pharmaceutical company headquartered in Moscow. It develops and markets medicines and dietary supplements, primarily in women's and men's health. The company was formerly part of Acino International and has operated independently in Russia under the Alcea brand since November 2023. Alcea ranks fifth by sales value in rubles among manufacturers of women's health products operating in the Russian market.
History The company has operated in the Russian market since 2015, initially under the Acino brand as part of the international Acino International (formerly Acino Rus). In 2023, Acino International's Russian business was separated into an independent company. It began operating under the Alcea brand in November 2023, retaining the product portfolio, business processes and team of the former operation.
According to a SCAN-Interfax ranking, Alcea's media visibility index increased from 12,000 in 2023 to 50,000 in 2024, while the estimated audience reach rose from 3 million to 14 million.
Alcea is a member of the Association of Health Products Industry.
Operations and financial performance By 2024, Alcea's share of the market segments in which it operates was approximately 10% by value, following five consecutive years of growth. Over the same five-year period, the company's business grew approximately fivefold. Alcea operates in all Russian cities with populations above one million, with Moscow and Saint Petersburg as its largest markets. Its products are sold through more than 50,000 pharmacies and online retailers; e-commerce accounts for approximately 16–17% of sales.
Products and therapeutic areas Alcea focuses on several therapeutic areas, including benign breast conditions, cervical disorders including dysplasia, vulvovaginal infections and inflammatory conditions of the female reproductive system, iron-deficiency anaemia, proctological conditions, and symptoms associated with menopause and perimenopause. Its portfolio is primarily aimed at conditions affecting women of reproductive and perimenopausal age.
As of September 2026, Alcea's portfolio comprised 21 medicine and dietary-supplement brands in women's health, proctology and urology. Brands in the portfolio include Indinol Forto, Cervicon-DIM, Neo-Penotran, Ferretab, Posterisan and Estrovel.
Manufacturing Alcea states that its products are manufactured in accordance with Good Manufacturing Practice (GMP) requirements and that the company is certified to ISO standards. Its manufacturing partners in Russia include MiraxBioPharma for Indinol Forto, Altpharm for Cervicon-DIMand VTF for several dietary supplements. The company also works with manufacturers in Austria, Germany and Turkey. Approximately 80% of Alcea's own products are manufactured in Russia.
Research and educational activities Alcea conducts research and development activities. In 2022–2023, the company carried out three research projects in Russia in cooperation with research centres. It also conducts clinical studies intended to support additional indications for some of its women's health products.
Cervicon-DIM is registered in Russia for the treatment of cervical dysplasia and is included in Russian Ministry of Health clinical guidelines. Research is continuing into its potential effects on human papillomavirus (HPV) infection. Rosstat data cited by Rossiyskaya Gazeta reported that the number of recorded cervical cancer cases in Russia increased from 41,200 in 2015 to 45,600 in 2024.
The company reports regular engagement with more than 15,000 gynaecologists across Russia and more than 1,600 educational events for physicians each year, covering gynaecology, mammology and the treatment of iron-deficiency anaemia. Its social, educational and charitable initiatives include the nationwide Rose of Health programme, which focuses on health education and disease prevention for women. Alcea has also participated in charitable projects with organisations including AdVITA, Oncologica and the Leukemia Foundation.
References